DAWN's Business Model
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://dayonebio.com |
| CEO (Chief Executive Officer) | Jeremy Bender |
| Number of Employees | |
| IPO date | May 27, 2021 |
DAWN Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 395 Oyster Point Boulevard |
| City | Brisbane |
| State | CA |
| Phone | 650 484 0899 |
| Zip Code | 94080 |
| Other Identifiers | |
| CIK | 0001845337 |
| ISIN | US23954D1090 |
| CUSIP | 23954D109 |
| Open | 12.2 |
| Previous Close | 12.07 |
| Volume | 3.46 Mil. |
| Average Volume | 2.94 Mil. |
| Day’s Range | 11.9701 – 13.135 |
| 52 Week Range | 5.635-13.53 |
| MA (50) | 9.3318 |
| MA (200) | 7.57338 |
| Market Cap | 1.27 Bil. |
| Shares Out. | 102.7 Mil. |
| Earnings Date | Mar 09, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
